Latest News

With continuous efforts to find new cancer treatments, comes to life a new ultrasound technology developed by a US based company called HistoSonics the device…

The EMA has published a draft guideline for public consultation that offers recommendations on how to include and/or continue pregnant and breastfeeding individuals in clinical…

Non-arteritic anterior ischemic optic neuropathy, or NAION, is a very rare eye condition that causes vision loss; it affects 1 in 10,000 patients taking Semaglutide…

We now live in a time where innovation & technology are shaping our future from mobile phones to life saving inventions. The UK government has…

As of 16th of May 2025 Guselkumab (Tremfya) has been approved for the treatment of Crohn’s disease & Ulcerative colitis. However, it was initially used…

With the rising risk of antibiotics resistance, EMA’s human medicines committee (CHMP) has decided on readjusting the use of some antibiotics like azithromycin and limiting…

With the AI being integrated in almost everything nowadays, FDA has decided to dive in and also integrate AI in their practice. AI has proven…

EMA’s safety committee, Pharmacovigilance Risk Assessment Committee (PRAC) recent review revealed negative mental health impact of finasteride and dutasteride on patients taking it for anti-hair loss…

As part of global efforts to protect the environment, the Medicines and Healthcare products Regulatory Agency (MHRA) is playing a role by supporting changes to…

The FDA has just recently approved a new blood test called The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, that helps with the early detection of…

With Kaftrio being used for treatment of patients with Cystic Fibrosis, comes serious negative impact on patient’s psychological state. As of 25 February 2025, the…

The UK Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for obecabtagene autoleucel (Aucatzyl)—a CAR T-cell therapy—for the treatment of adult patients…

The U.S. Food and Drug Administration (FDA) has taken the initiative to stop the use of concentrated ingestible fluoride present in prescription drugs of children.…

As of 30 April 2025, a new formulation for Nivolumab has been approved by The Medicines and Healthcare products Regulatory Agency (MHRA) making the treatment…

The UK’s Medicines & Healthcare Products Regulatory agency has approved Acoramidis (Beyonttra) for the treatment of adult patients with cardiomyopathy caused by transthyretin amyloidosis (ATTR-CM),…